Taysha Gene Therapies (NASDAQ: TSHA)
$1.88
(-8.3%)
-$0.17
Price as of January 7, 2025, 1:51 p.m. ET
Taysha Gene Therapies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Taysha Gene Therapies Company Info
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.